Two Onc Docs

ASCO 2025 Plenary - MATTERHORN

Season 4 Episode 16

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.